Cancer

Researchers develop promising way to find new cancer drugs


Researchers develop promising way to find new cancer drugs
Microarray slides that the researchers use to investigate enzyme interactions. Credit: Carlos Moreno Yruela

All the cells in the human body share the same genes. But how our genes are expressed determines whether a cell becomes a brain cell or a liver cell. In addition, changes in gene expression often play a significant role in development of diseases.

One mechanism that contributes to the changes in gene expression is the interaction between the proteins called histones and enzymes known as HDACs. These enzymes help the cell divide and develop, which is the reason why they serve as targets for anti-cancer medicine: When you inhibit the enzymes, the cancer cells will stop dividing and growing further.

Read:As seasons change, so should diet for breast cancer survivors

Despite being targets for clinically approved medicines, researchers do not know all the details of how they work in the cell. Now, researchers from the University of Copenhagen have developed a method that will help change that.

“We have shown details of how these enzymes interact with proteins around our DNA, and our method provides a new means for identifying possible anti-cancer drugs very quickly. In the study, we show that the method works: We synthesized a peptide that affected just the right parts of living human cells, using the same target as anti-cancer medicine uses today,” says Carlos Moreno-Yruela, postdoc at the Department of Drug Design and Pharmacology.

Unmodified peptide had effect

HDACs are a group of eleven different enzymes, which means that targeting them all at once with a non-selective medicine will result in affecting many essential processes in the body. This may also explain some of the side effects in the clinically approved HDAC-inhibiting anti-cancer medicine.

“Our detailed insight into the enzymes’ interactions gained with the new method provide hope for the development of more specific HDAC inhibitors with potential as drug candidates. This could bode well for the development of more sophisticated compounds for cancer therapy with fewer side effects,” says Professor Christian Adam Olsen.

Read:Genetic tool improves estimation of prostate cancer risk in diverse ethnic/racial groups

In the study, the researchers used the new method for identifying peptides, which they resynthesized in larger amounts and subjected to human cells. The results were exactly what they hoped: The expected HDACs were also inhibited in living cells.

“We were surprised to see such a prominent effect of an unoptimized peptide in cells. Normally, one would need to introduce a variety of modifications to optimize its properties. But this, almost fully natural, peptide had a really potent effect, which emphasizes the potential of our findings,” says Christian Adam Olsen.

The researchers now hope to use the method for identifying promising drug candidates which could go on to pre-clinical testing.

Read:Treating spinal metastases with fewer, higher doses of radiation reduces pain more effectively

Enzyme could prove effective in treating tumors and inflammatory diseases in lung: study


More information:
Carlos Moreno-Yruela et al, Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases, Nature Communications (2021). DOI: 10.1038/s41467-020-20250-9

Provided by
University of Copenhagen

Citation:
Researchers develop promising way to find new cancer drugs (2021, January 25)
retrieved 25 January 2021
from https://medicalxpress.com/news/2021-01-cancer-drugs.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Previous post
First observation of the early association between proteins linked to Alzheimer’s disease
Next post
Vaccine May Keep Melanoma in Remission 4 Years